title: Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.
abstract: OBJECTIVE
  Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancer patients. We hypothesized that carboplatin-etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide.
  
  
  METHODS
  We enrolled 15 patients in the first step of a Phase II trial. The target sample size is 46 patients. The primary end point of the study was progression-free survival after 12 weeks.
  
  
  RESULTS
  The median progression-free survival was 11 weeks (range: 8-18), while median overall survival was 18 weeks (range: 12-26). Of seven patients with measurable disease, two had a partial response, two showed stable disease and the remaining three had progressive disease as the best radiological response. Five patients were considered progression-free after 12 weeks, prompting continuation of the trial.
  
  
  CONCLUSIONS
  Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer.
authors: Genitourinary Cancer Section, Medical Oncology Division, Department of Clinical Medicine, University Federico II, Napoli, Italy.
authors: Carlo
authors: C
authors: Buonerba
authors: Piera
authors: P
authors: Federico
authors: Davide
authors: D
authors: Bosso
authors: Livio
authors: L
authors: Puglia
authors: Tania
authors: T
authors: Policastro
authors: Michela
authors: M
authors: Izzo
authors: Francesco
authors: F
authors: Perri
authors: Giuseppina Della
authors: GD
authors: Vittoria Scarpati
authors: Matteo
authors: M
authors: Ferro
authors: Ottavio De
authors: OD
authors: Cobelli
authors: Sabino
authors: S
authors: De Placido
authors: Michele
authors: M
authors: Aieta
authors: Ciro
authors: C
authors: Imbimbo
authors: Nicola
authors: N
authors: Longo
authors: Giuseppe
authors: G
authors: Di Lorenzo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D016190:Carboplatin; D017430:Prostate-Specific Antigen
keywords: abiraterone; carboplatin; enzalutamide; etoposide; neuroendocrine; prostate cancer